Objective: Hypertension becomes more prevalent in women during their postmenopausal years. Nighttime systolic blood pressure (SBP) is especially predictive of adverse cardiac events, and the relationship between rising nighttime SBP and cardiovascular risk increases more rapidly in women compared with men. The reasons for the prognostic significance of nighttime SBP are not completely known but may involve vascular endothelial dysfunction. The purposes of this study were to examine the relationship between nighttime SBP and endothelial function, as assessed by brachial artery flow-mediated dilation (FMD), and to determine whether postmenopausal women with nighttime hypertension (SBP Q120 mm Hg) evidenced greater endothelial dysfunction compared with women with normal nighttime SBP.
C ardiovascular morbidity increases with age; however, on average, women are 10 years older than men when they develop cardiovascular disease. 1 Consequently, most cardiovascular events in women occur during their postmenopausal years. Cardiovascular risk is multifactorial, but estrogen decline may also contribute to greater cardiovascular disease among postmenopausal women. Postmenopausal women have reduced endothelial function compared with premenopausal women, 2,3 and estrogen supplementation has been found to improve endothelial function in some postmenopausal women. 4 These findings suggest that estrogen withdrawal associated with menopause may, in part, adversely affect vascular function. Menopausal transition is also associated with increasing prevalence of hypertension, becoming equivalent to and then surpassing that of men after age 65 years. 1 Postmenopausal women with hypertension have reduced endothelial function in comparison with postmenopausal women with normotension. 5 Taken together, these findings suggest that menopause and hypertension negatively affect endothelial function.
Unlike menopause, hypertension is a major modifiable cardiovascular risk factor. Among all blood pressure (BP) parameters, nighttime systolic BP (SBP) is most predictive of adverse cardiovascular events in both hypertensive cohorts and general populations. 6<9 Interestingly, as nighttime SBP rises, the relationship between BP and cardiovascular risk increases more rapidly in women than in men. 10, 11 The reasons for the prognostic significance of nighttime SBP are not completely known but may involve impaired endothelial function. Functional changes in the endothelium are considered to emerge early in the atherosclerotic disease process. 12 Endothelial function can be assessed noninvasively via ultrasound measurement of brachial artery vasodilator responses to hyperemic blood flow (flow-mediated dilation [FMD] ). 13 Endothelial dysfunction, quantified as reduced FMD, is a predictor of cardiovascular events in general populations, 14, 15 individuals with cardiac conditions and hypertension, 16, 17 and postmenopausal women. 18 Although higher office BP, 19<22 home BP, 19 24-hour ambulatory BP, 23, 24 and BP nondipping 25, 26 are associated with greater endothelial dysfunction, less is known regarding the relationship between nocturnal hypertension and endothelial function. There is some evidence for an inverse association between FMD and nighttime SBP in individuals with hypertension or coronary heart disease. 27, 28 However, these previous studies included few women, and no studies have evaluated the relationship between nighttime SBP and FMD in postmenopausal women. Given that postmenopausal women are at higher risk for cardiovascular disease and that the relationship between nighttime SBP and cardiovascular risk increases more drastically in woman than in men, the objectives of this study were (1) to evaluate whether nighttime SBP is associated with endothelial function (FMD) and (2) to evaluate the hypothesis that endothelial function in postmenopausal women with nighttime hypertension (nighttime SBP Q120 mm Hg) is impaired relative to postmenopausal women with normal nighttime SBP (G120 mm Hg).
METHODS

Participants
The sample consisted of 100 postmenopausal women aged between 50 and 80 years who participated in the ENDEAVOR study at Duke University Medical Center. The methodology of ENDEAVOR had been reported previously. 4 In brief, ENDEAVOR was a randomized, double-blind, cross-over study that examined the immediate effects of transdermal estrogen therapy (17A-estradiol 0.05 mg/d), estrogen-progesterone therapy (17A-estradiol 0.05 mg/d + norethindrone acetate 0.14 mg/d), and placebo on cardiovascular parameters and endothelial function. Participants in the current analysis were women randomized to a placebo transdermal patch who had 24-hour ambulatory BP monitoring (ABPM) recordings (Q15 daytime and Q5 nighttime readings) and who completed FMD testing. 4 Postmenopause status was defined as amenorrhea for 12 months or more and was confirmed by a reproductive hormone panel. Exclusion criteria included the following: use of hormone therapy or selective estrogen receptor modulators within 30 days of enrollment; congestive heart failure higher than New York Heart Association class II; pacemaker dependency; uncontrolled hypertension (defined as resting BP Q180/105 mm Hg); persistent atrial fibrillation or tachyarrhythmia; myocardial infarction and/or percutaneous transluminal coronary angioplasty within 30 days of enrollment; coronary artery bypass grafting within 3 months of enrollment; uncorrected valvular disease; hypertrophic or restrictive cardiomyopathy; uncorrected thyroid disease; renal or hepatic dysfunction; dementia; or body mass index (BMI) of 40 kg/m 2 or higher. Participants were recruited from Duke University cardiology clinics and by advertisements in the Piedmont region of North Carolina. The study protocol was approved by the Institutional Review Board at Duke University Medical Center. All eligible individuals provided a written informed consent form before participation in the study.
Demographic, anthropometric, and biochemical assessment
Data on age, ethnicity, current cigarette smoking, time since menopause, previous cardiovascular disease (angina, coronary artery disease [defined as Q50% occlusion of one or more major coronary vessels on cardiac catheterization], myocardial infarction, peripheral vascular disease, stroke, and transient ischemic attack), diagnosis of diabetes and/or hypertension, and current cardiovascular medications (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, A-blockers, calcium channel blockers, diuretics, nitrates, and statins) were collected by medical records review and self-report. Blood samples were collected in the morning after an overnight fast. Specimens were analyzed by Labcorp using automated enzymatic assays for total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides.
Clinic BP measurement
Clinic BP was measured after a 5-minute quiet seated rest period in a temperature-controlled room. Five standard auscultatory BP readings, at 2-minute intervals, were taken using a mercury sphygmomanometer and a stethoscope. The average of the last three readings was used to represent clinic SBP and clinic diastolic BP (DBP).
24-Hour ABPM
Participants were instrumented with the validated noninvasive Oscar 2 oscillometric ambulatory blood pressure monitor (SunTech, Raleigh, NC) 29,30 between 11:00 AM and 1:00 PM on a weekday. SBP and DBP were measured every 20 minutes during the day and every 30 minutes during the night for the consecutive 24-hour period. Waking and sleep periods, defined by self-report and confirmed by a wristwatchstyle ActiGraph (ActiWatch64; Mini-Mitter Co Inc, Sunriver, OR), were used to compute mean daytime BP and mean nighttime BP, respectively. The ActiGraph was also used to provide a measure of physical activity while awake. Artifactual ABPM readings were identified by the Oscar 2 ABPM software. At least 15 daytime ABPM recordings and at least 5 nighttime ABPM recordings were necessary for inclusion in the analysis. For the study sample (N = 100), the mean (SD) daytime ABPM reading was 35.6 (8.2), and the mean (SD) nighttime ABPM reading was 16.4 (3.6). Nighttime SBP was further categorized into nighttime hypertension (SBP Q120 mm Hg) 31 and normal nighttime BP (SBP G120 mm Hg). 32, 33 A nighttime SBP threshold of 120 mm Hg or higher for nighttime hypertension has been used in previous studies. 34<37 858 Menopause, Vol. 22, No. 8, 2015 Assessment of endothelial function FMD assessment was carried out for a minimum of 4 hours after a light, fat-free, caffeine-free breakfast, which was provided as part of the study. Participants refrained from using vasoactive medications from 12 AM the night before until after FMD assessment had been completed. Adherence to these instructions was confirmed before testing.
Endothelial function assessments of the brachial artery were performed as previously described. 4 Longitudinal Bmode images of the brachial artery, in the region 4 to 6 cm proximal to the antecubital fossa, were recorded by the same sonographer and stored digitally using a 7-to 11-MHz lineararray transducer and Aspen ultrasound system (Acuson, Mountain View, CA). For FMD assessment, images were captured after 10 minutes of supine rest and during the first 120 seconds of reactive hyperemia, achieved by inflation of a pneumatic occlusion cuff (located around the forearm) to suprasystolic pressure (È200 mm Hg) for 5 minutes. Enddiastolic images were stored, and arterial diameters were measured as the distance between the proximal and the distal arterial wall intima-media interfaces using PC-based software (Brachial Analyzer version 5.0; Medical Imaging Applications LLC, Iowa City, IA). Peak FMD response was assessed from 10 to 120 seconds after deflation of the cuff, with peak arterial diameter quantified using polynomial curve fitting.
FMD was initially expressed as the percentage increase in arterial diameter (maximal arterial diameter j baseline arterial diameter/baseline arterial diameter Â 100%), the index adopted most widely. 38 Given that the percentage change index may result in bias toward greater vasodilation in smaller arteries, 38, 39 baseline arterial diameter was used as covariate in multivariate analyses.
All FMD studies were conducted in our research facility (using the same Acuson Aspen ultrasound machine), were obtained by the same research sonographer, and were analyzed and quantified by the same observer (A.S.) who was blinded to the identity of the image source. In an unpublished evaluation of 20 healthy men and women who underwent our FMD assessment protocol on two consecutive days, repeated FMD values showed an r value of 0.81 (P G 0.001), and a mean (SD) difference of 0.64% (2.67%).
Statistical analysis
Normality statistics (skew, kurtosis, and Kolmogorov-Smirnov), histograms, box plots, and normal probability plots were examined to assess normality. Results are presented as mean (SD) for continuous variables and as frequency (percentage) for categorical variables. Student's t test, Wilcoxon two-sample test (HDL cholesterol and triglycerides), and W 2 test were used to compare the characteristics of study participants with nighttime hypertension and normal nighttime SBP. Simple correlations between participant characteristics and FMD responses were described using Pearson's r correlations for continuous variables and Spearman's r correlations for categorical variables. SBP parameters (daytime, nighttime, 24 h, and clinic) were found to correlate with FMD. When all four SBP parameters were entered into a regression model predicting FMD, variance inflation factors were greater than 2, indicating the presence of multicollinearity, as expected. Given the related nature of these SBP variables, the stepwise variable selection method (P G 0.05 for variable entry; P 9 0.10 for removal) in model 1 was initially used to assess the relationship between SBP parameter and FMD. The only variable retained in model 1 was mean nighttime SBP. Therefore, the purpose of model 2 was to examine the relationship between mean nighttime SBP and FMD after considering baseline artery diameter and participant characteristics (age, BMI, race/ethnicity, smoking, daytime physical activity, diabetes, high cholesterol, cardiovascular disease, total cholesterol, HDL cholesterol, cardiovascular medications, and BP medications) using the stepwise variable selection method (P G 0.05 for variable entry; P 9 0.10 for removal). As a follow-up to model 2, analysis of covariance was used to compare FMD means between the nighttime hypertension group and the normal nighttime SBP group to adjust for the covariance of baseline artery diameter associated with FMD in regression analysis. Statistical analyses were conducted using the SAS version 9.3 system (SAS Institute, Cary, NC), with significance set at P = 0.05. Table 1 summarizes the demographic and clinical characteristics of the 100 postmenopausal women who composed the study sample. Women with nighttime hypertension were older and had lower HDL cholesterol, greater clinic SBP, mean daytime BP, mean nighttime BP, 24-hour ambulatory BP, diabetes, hypertension, and lower FMD.
RESULTS
Initial bivariate correlational analyses
Variables significantly associated with FMD included baseline artery diameter (r = j0.38, P G 0.001), clinic SBP (r = j0.28, P = 0.005), clinic DBP (r = j0.26, P = 0.011), mean daytime SBP (r = j0.31, P = 0.002), mean nighttime SBP (r = j0.38, P G 0.001), mean daytime DBP (r = j0.27, P = 0.006), mean nighttime DBP (r = j0.40, P G 0.001), 24-hour ambulatory SBP (r = j0.36, P G 0.001), 24-hour ambulatory DBP (r = j0.33, P = 0.001), nocturnal SBP hypertension (r s = j0.34, P G 0.001), history of diabetes (r s = j0.23, P = 0.024), and calcium channel blocker use (r s = j0.20, P = 0.043). No other variables correlated with FMD at the level of significance (P = 0.05).
Regression analyses
Because of the significant bivariate relationships found between BP parameters (all r's 9 0.48; all P's G 0.001), the stepwise variable selection method was used to identify BP variables significantly associated with FMD. When considering all SBP parameters (daytime, nighttime, 24 h, and clinic), as expected, only mean nighttime SBP was significantly associated with FMD (Table 2, model 1). Mean nighttime SBP accounted for approximately 14% of the FMD variance. In model 2 (Table 2) , we considered the potential relationships between mean nighttime SBP, baseline artery diameter, participant characteristics (age, BMI, ethnicity, smoking status, daytime physical activity, diabetes, high cholesterol, cardiovascular disease, total cholesterol, HDL cholesterol, cardiovascular medications, and BP medications) and FMD. Mean nighttime SBP and baseline artery diameter were significantly and inversely associated with FMD, following the stepwise variable selection method for multivariate regression. Baseline artery diameter contributed to an additional 9% of FMD variance. No other participant characteristics were significantly associated with FMD.
FMD and nocturnal SBP
The sample was divided into postmenopausal women with nighttime hypertension and postmenopausal women with normal nighttime SBP. Analysis of covariance indicated that women with nighttime hypertension had lower mean (SD) FMD than those with normal nighttime SBP (2.95% [0.65%] vs 5.52% [0.46%]; F 1,97 = 10.18, P = 0.002) after adjustment for baseline artery diameter (P G 0.001).
DISCUSSION
The main finding of our study was that impaired endothelial function, as indicated by reduced brachial artery FMD, was G0.001 Baseline artery diameter, mean (SD), mm 3.7 (0.8) 3.6 (0.7) 3.9 (0.8) 0.051 Normal nighttime SBP indicates a mean nighttime SBP lower than 120 mm Hg. Nighttime hypertension indicates a mean nighttime SBP of 120 mm Hg or higher. BP, blood pressure; BMI, body mass index; SBP, systolic BP; DBP, diastolic BP; CAD, coronary artery disease; MI, myocardial infarction; PVD, peripheral vascular disease; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; HDL, high-density lipoprotein; LDL, low-density lipoprotein; FMD, flow-mediated dilation. associated with greater mean nighttime SBP and larger baseline artery diameter. Women with nighttime hypertension exhibited FMD responses that were approximately 2.5% lower than the FMD responses of women with normal nighttime SBP. These findings are significant given that a recent meta-analysis 40 found that a 1% decrease in FMD was associated with an 8% to13% increase in the risk of future cardiovascular events. To our knowledge, this is the first study to report an inverse association between nighttime SBP and FMD in postmenopausal women. This finding is especially noteworthy because the risk of adverse cardiac events is increased in postmenopausal women and may be mediated, in part, by impaired endothelial function.
There are a limited number of studies that have examined the relationship between endothelial function and nighttime SBP in men and women. For example, Konrad et al 27 reported that higher mean (SD) nighttime SBP was associated with reduced endothelial function (FMD) in 49 individuals (53.5 [8.9] y; 20 women) with treated hypertension. In a study of 73 individuals (20 women) with stable coronary artery disease, nighttime SBP correlated with FMD (r = j0.31, P G 0.01), but multivariate associations were not reported. 28 Ward et al 24 described an inverse relationship between 24-hour SBP and FMD responses, but without examining the relationship between nighttime SBP and FMD. Our study extends prior research to include postmenopausal women and may identify a group of women at higher cardiovascular risk because of poorer endothelial function.
Endothelial dysfunction has been proposed as a gauge of cardiovascular risk. 41 Meta-analyses have found brachial FMD impairment to be predictive of future cardiovascular events, with some studies indicating a stronger relationship in diseased populations. 40, 42 Specifically in postmenopausal women, poorer endothelial function was found to be an independent predictor of cardiovascular events in 400 women with hypertension 43 and an independent predictor of cardiovascular risk beyond traditional cardiovascular risk factors in 2,264 initially asymptomatic postmenopausal women with risk factors for atherosclerosis. 18 Antihypertensive therapy has been shown to improve FMD, 44 with some studies suggesting that aldosterone inhibition may improve endothelial function beyond its BP-lowering effects in postmenopausal women. 45 The prognostic significance of improved FMD was reported by Modena et al. 43 In this study, hypertensive postmenopausal women whose FMD improved after a 6-month treatment of clinic BP to target levels (G140/90 mm Hg) had a more favorable cardiovascular prognosis compared with treated hypertensive postmenopausal women whose FMD had not improved. 43 ABPM was not within the scope of the study by Modena et al 43 ; therefore, the effect of treatment on nighttime SBP and FMD could not be assessed. However, the findings of our study raise the possibility that nighttime SBP could have played a partial role in hypertensive postmenopausal women who achieved clinic BP control but lacked improvement in FMD.
Several prospective studies have found nighttime SBP, compared with daytime or 24-hour ambulatory BP, to be the most significant prognostic marker of cardiovascular disease morbidity and mortality. 6<9,46,47 Recently, Hermida et al 48 found nighttime SBP to be the most significant predictor of cardiovascular events in more than 3,300 normotensive and hypertensive individuals prospectively studied for 5.6 years. This relationship remained significant after adjustment for daytime SBP, age, sex, and diabetes. During follow-up, a progressive decrease in sleeping BP was the most significant predictor of event-free survival; a 5-mm Hg decrease in mean nighttime (sleeping) SBP was associated with a 17% reduction in cardiovascular risk. These findings support decreasing nighttime BP as an approach to reducing cardiovascular disease risk. 48 Compared with the typical morning administration of antihypertensive medications, nighttime (bedtime) administration of one or more antihypertensive medications had a greater impact on reducing nighttime BP 49, 50 and was associated with reduced cardiovascular disease risk in general hypertensive individuals 50, 51 and in cohorts of hypertensive individuals with resistant hypertension, 52 type 2 diabetes mellitus, 53 and chronic kidney disease. 54 Therefore, one may speculate that reductions in BP at night may ameliorate cardiovascular risk in part via favorable changes in endothelial function.
Limitations
Because our study employed a cross-sectional design, we cannot infer that nighttime hypertension was causally related to impaired endothelial function. Furthermore, our findings Variables considered for model 2: mean nighttime SBP, baseline artery diameter, age, body mass index, ethnicity, smoking status (0, nonsmoker; 1, fewer than one-half pack daily; 2, one-half to one pack daily), daytime physical activity, diabetes (0, no; 1, yes), high cholesterol (0, no; 1, yes), cardiovascular disease (0, no history of coronary artery disease, myocardial infarction, peripheral vascular disease, or stroke; 1, history of coronary artery disease, myocardial infarction, peripheral vascular disease, or stroke), total cholesterol, high-density lipoprotein cholesterol, cardiovascular medications (0, no; 1, yes), and blood pressure medications (0, no; 1, yes). b, nonstandardized (parameter estimate) regression coefficient; A, standardized regression coefficient; SBP, systolic blood pressure. are limited to postmenopausal women; we did not study premenopausal women or men. Nevertheless, study of postmenopausal women is important because postmenopausal women are at greater cardiovascular risk than premenopausal women, and cardiovascular risk increases more dramatically during these years for women than for men. Another limitation of the study was the measurement of only one 24-hour ABPM session. It could be argued that additional ABPM sessions may increase the reproducibility of the BP findings. However, 24-hour monitoring is considered the standard in clinical practice and generates BP readings that are probably more representative of true BP compared with clinic BP measurements. Coronary angiography (in women without coronary artery disease), overnight polysomnography, and pulmonary dysfunction assessments were not included in the study design. Therefore, it is possible that the extent of atherosclerosis, sleep depth, sleep disorders, and pulmonary dysfunction, as well as unrecognized confounding factors, may have contributed to individual differences in nighttime BP. Study strengths include the use of actigraphy for the objective determination of awake and asleep periods and for a more accurate calculation of mean daytime and nighttime BP.
CONCLUSIONS
Nighttime SBP is associated with reduced endothelial function. Our findings raise the possibility that normalization of nighttime SBP may improve endothelial function and cardiovascular risk. Research examining the therapeutic benefits of nighttime hypertension treatment on endothelial function and future cardiovascular risk in postmenopausal women is warranted.
